23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ALNYLAM PHARMACEUTICALS INC. › 2023-2024

ALNYLAM PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 503Asset managers, any item
  • 3,855Fund votes
  • May 16, 2024Meeting date

Results at a glance

Meeting of May 16, 2024: 6 items on ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024: 4 elected · 2 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALNYLAM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ALNYLAM PHARMACEUTICALS INC.

These tallies are ALNYLAM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALNYLAM PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 16, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dennis A. Ausiello, M.D. 103,971,5328,960,23514,285 --4,991,057 92%Elected—
Elect Director: Olivier Brandicourt, M.D. 106,444,2016,487,47214,379 --4,991,057 94%Elected—
Elect Director: Peter N. Kellogg 108,577,0154,354,57714,460 --4,991,057 96%Elected—
Elect Director: David E.I. Pyott 102,273,20910,658,27814,565 --4,991,057 91%Elected—
2. Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting 106,783,2626,133,62829,162 --4,991,057 95%Approved—
3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 114,460,1153,456,32620,668 --0 97%Approved—

This meeting is also recorded here as May 17, 2024; both records come from the same filing, so the date should be checked against it.

Source: ALNYLAM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 20, 2024 — read the filing on EDGAR.

How asset managers voted at the ALNYLAM PHARMACEUTICALS INC. 2023-2024 meeting

503 asset managers disclosed a vote on at least one ALNYLAM PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: David E.I. Pyott

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 102,273,209AGAINST: 10,658,278
Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David E.I. Pyott”): 102,273,209 for, 10,658,278 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 60,356,958 for, 5,409,246 against, 6,114 abstained.

FOR
FOR: 60,356,958AGAINST: 5,409,246ABSTAIN: 6,114
Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard18,597,2940 00For
Capital Group14,436,0510 00For
Fidelity9,412,3850 00For
T. Rowe Price04,521,656 00Against
BlackRock3,341,5380 00For
AMCAP FUND3,331,9710 00For
Dodge & Cox2,854,3410 00For
American Century1,028,3160 00For
JPMorgan1,000,9460 00For
NEW ECONOMY FUND888,4870 00For
State Street571,157130 00For
Jackson National306,432251,010 00Mixed
TIAA539,3480 00For
Charles Schwab442,6240 00For
Equitable172,03751,639 00Mixed
First Trust219,8630 00For
BNY Mellon206,7030 00For
OLD WESTBURY FUNDS INC194,0040 00For
CARILLON SERIES TRUST192,5390 00For
MassMutual1,795187,332 00Against
Aberdeen174,0150 00For
John Hancock124,09849,226 00Mixed
FRANKLIN STRATEGIC SERIES148,4000 00For
Federated Hermes147,7000 00For
Dimensional136,8700 00For

Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).

Elect Director: Dennis A. Ausiello, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 103,971,532AGAINST: 8,960,235
Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dennis A. Ausiello, M.D.”): 103,971,532 for, 8,960,235 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 60,426,871 for, 5,339,333 against, 6,114 abstained.

FOR
FOR: 60,426,871AGAINST: 5,339,333ABSTAIN: 6,114
Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard18,597,2940 00For
Capital Group14,436,0510 00For
Fidelity9,412,3850 00For
T. Rowe Price04,521,656 00Against
BlackRock3,341,5380 00For
AMCAP FUND3,331,9710 00For
Dodge & Cox2,854,3410 00For
American Century1,028,3160 00For
JPMorgan1,000,9460 00For
NEW ECONOMY FUND888,4870 00For
State Street571,074213 00For
Jackson National306,432251,010 00Mixed
TIAA539,3480 00For
Charles Schwab442,6240 00For
Equitable172,03751,639 00Mixed
First Trust219,8630 00For
BNY Mellon206,7030 00For
OLD WESTBURY FUNDS INC194,0040 00For
CARILLON SERIES TRUST192,5390 00For
MassMutual1,795187,332 00Against
Aberdeen174,0150 00For
John Hancock124,09849,226 00Mixed
FRANKLIN STRATEGIC SERIES148,4000 00For
Federated Hermes147,7000 00For
Dimensional136,8700 00For

Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).

Elect Director: Olivier Brandicourt, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 106,444,201AGAINST: 6,487,472
Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Olivier Brandicourt, M.D.”): 106,444,201 for, 6,487,472 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 62,548,914 for, 3,217,290 against, 6,114 abstained.

FOR
FOR: 62,548,914AGAINST: 3,217,290ABSTAIN: 6,114
Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard18,597,2940 00For
Capital Group14,436,0510 00For
Fidelity9,412,3850 00For
T. Rowe Price1,664,1872,857,469 00Mixed
BlackRock3,341,5380 00For
AMCAP FUND3,331,9710 00For
Dodge & Cox2,854,3410 00For
American Century1,028,3160 00For
JPMorgan1,000,9460 00For
NEW ECONOMY FUND888,4870 00For
State Street571,22562 00For
Jackson National557,4420 00For
TIAA539,3480 00For
Charles Schwab442,6240 00For
Equitable172,03751,639 00Mixed
First Trust219,8630 00For
BNY Mellon14,353192,350 00Mixed
OLD WESTBURY FUNDS INC194,0040 00For
CARILLON SERIES TRUST192,5390 00For
MassMutual189,1270 00For
Aberdeen174,0150 00For
John Hancock124,09849,226 00Mixed
FRANKLIN STRATEGIC SERIES148,4000 00For
Federated Hermes147,7000 00For
Dimensional136,8700 00For

Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).

Elect Director: Peter N. Kellogg

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 108,577,015AGAINST: 4,354,577
Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Peter N. Kellogg”): 108,577,015 for, 4,354,577 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company's 2027 annual meeting of stockholders or until his successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 62,773,501 for, 2,992,703 against, 6,114 abstained.

FOR
FOR: 62,773,501AGAINST: 2,992,703ABSTAIN: 6,114
Largest asset managers voting on “To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard18,597,2940 00For
Capital Group14,436,0510 00For
Fidelity9,412,3850 00For
T. Rowe Price1,664,1872,857,469 00Mixed
BlackRock3,341,5380 00For
AMCAP FUND3,331,9710 00For
Dodge & Cox2,854,3410 00For
American Century1,028,3160 00For
JPMorgan1,000,9460 00For
NEW ECONOMY FUND888,4870 00For
State Street571,22562 00For
Jackson National557,4420 00For
TIAA539,3480 00For
Charles Schwab442,6240 00For
Equitable172,03751,639 00Mixed
First Trust219,8630 00For
BNY Mellon206,7030 00For
OLD WESTBURY FUNDS INC194,0040 00For
CARILLON SERIES TRUST192,5390 00For
MassMutual189,1270 00For
Aberdeen174,0150 00For
John Hancock124,09849,226 00Mixed
FRANKLIN STRATEGIC SERIES148,4000 00For
Federated Hermes147,7000 00For
Dimensional136,8700 00For

Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).

2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 23 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 106,783,262AGAINST: 6,133,628
Details: description as filed, official tally, votes by 503 asset managers

Description as filed by funds: To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers. The voting”): 106,783,262 for, 6,133,628 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 125 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard18,597,2940 00For
Capital Group14,436,0510 00For
Fidelity9,412,3850 00For
T. Rowe Price4,464,57557,081 00For
BlackRock3,341,5380 00For
AMCAP FUND3,331,9710 00For
Dodge & Cox2,854,3410 00For
American Century01,028,316 00Against
JPMorgan1,000,9460 00For
NEW ECONOMY FUND888,4870 00For
State Street571,2870 00For
Jackson National557,4420 00For
TIAA539,3480 00For
Charles Schwab442,6240 00For
Equitable223,6760 00For
First Trust219,8630 00For
BNY Mellon14,353192,350 00Mixed
OLD WESTBURY FUNDS INC194,0040 00For
CARILLON SERIES TRUST192,5390 00For
MassMutual189,1270 00For
Aberdeen0174,015 00Against
John Hancock173,3240 00For
FRANKLIN STRATEGIC SERIES148,4000 00For
Federated Hermes147,7000 00For
Dimensional136,8700 00For

Fund voting reports, all 125 managers: 64,170,134 for, 1,560,913 against, 5,207 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 408 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group16,553,2480 00For
Fidelity9,796,70710,224 00For
Wellington6,981,0730 00For
T. Rowe Price6,394,932115,403 00For
BlackRock4,466,5210 00For
Dodge & Cox3,540,7900 00For
Capital Research Global Investors3,136,8450 00For
State Street2,765,5950 00For
BAILLIE GIFFORD & CO LTD2,426,9310 00For
GEODE CAPITAL MANAGEMENT, LLC1,987,5750 00For
Man Group plc1,821,6400 00For
BAILLIE GIFFORD OVERSEAS LTD1,570,4440 00For
JPMorgan1,534,4570 00For
American Century01,123,799 00Against
Northern Trust730,9922,751 00For
PICTET ASSET MANAGEMENT SA686,2640 00For
Legal & General Investment Management Ltd0617,424 00Against
Nuveen544,1900 00For
UBS0521,780 00Against
Charles Schwab501,5860 00For
Desjardins Global Asset Management Inc.0392,352 00Against
Amundi0351,577 00Against
Newton Investment Management North America, LLC0331,533 00Against
Mitsubishi UFJ Trust & Banking Corp317,3500 00For
MELLON INVESTMENTS Corp311,4410 00For

Institutional-manager reports, all 408 managers: 75,649,679 for, 5,135,738 against, 1,433 not voted, 3 unknown. Showing the 25 largest; every one is in the interactive database (link above).

The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 114,460,115AGAINST: 3,456,326
Details: description as filed, official tally, votes by 130 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024”): 114,460,115 for, 3,456,326 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 130 asset managers below reported 65,543,601 for, 223,603 against, 5,207 abstained.

FOR
FOR: 65,543,601AGAINST: 223,603ABSTAIN: 5,207
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at ALNYLAM PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard18,597,2940 00For
Capital Group14,436,0510 00For
Fidelity9,412,3850 00For
T. Rowe Price4,521,6560 00For
BlackRock3,341,5380 00For
AMCAP FUND3,331,9710 00For
Dodge & Cox2,854,3410 00For
American Century1,028,3160 00For
JPMorgan1,000,9460 00For
NEW ECONOMY FUND888,4870 00For
State Street571,20483 00For
Jackson National557,4420 00For
TIAA539,3480 00For
Charles Schwab442,6240 00For
Equitable223,6760 00For
First Trust219,8630 00For
BNY Mellon206,7030 00For
OLD WESTBURY FUNDS INC194,0040 00For
CARILLON SERIES TRUST192,5390 00For
MassMutual189,1270 00For
Aberdeen0174,015 00Against
John Hancock173,3240 00For
FRANKLIN STRATEGIC SERIES148,4000 00For
Federated Hermes147,7000 00For
Dimensional136,8700 00For

Showing the 25 largest of 130 asset managers. All 130 are in the interactive database (link above).

Largest ALNYLAM PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 126,463,000 shares outstanding at the time of that meeting.

Fund voting reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 14.71%
2Capital Group 11.42%
3Fidelity 7.44%
4T. Rowe Price 3.58%
5BlackRock 2.64%
6AMCAP FUND 2.63%
7Dodge & Cox 2.26%
8American Century 0.81%
9JPMorgan 0.79%
10NEW ECONOMY FUND 0.70%
Institutional-manager reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Capital Group 13.09%
2Fidelity 7.75%
3Wellington 5.52%
4T. Rowe Price 5.15%
5BlackRock 3.53%
6Dodge & Cox 2.80%
7Capital Research Global Investors 2.48%
8State Street 2.19%
9BAILLIE GIFFORD & CO LTD 1.92%
10GEODE CAPITAL MANAGEMENT, LLC 1.57%

Reported ALNYLAM PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ALNYLAM PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)16,767,625 13.26%Form 13F, quarter ended March 31, 2024
Vanguard Group13,565,452 10.73%Form 13F, quarter ended March 31, 2024
BlackRock9,903,601 7.83%Form 13F, quarter ended March 31, 2024
Wellington Management7,209,005 5.70%Form 13F, quarter ended March 31, 2024
JPMorgan Chase4,543,770 3.59%Form 13F, quarter ended March 31, 2024
T. Rowe Price3,685,753 2.91%Form 13F, quarter ended March 31, 2024
Capital International3,651,217 2.89%Form 13F, quarter ended March 31, 2024
State Street3,191,373 2.52%Form 13F, quarter ended March 31, 2024
Geode Capital2,001,718 1.58%Form 13F, quarter ended March 31, 2024
Norges Bank1,521,412 1.20%Form 13F, quarter ended March 31, 2024

Percentages above are of 126,463,000 shares outstanding, as reported by ALNYLAM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ALNYLAM PHARMACEUTICALS INC.'s shareholder meeting held May 16, 2024, in the 2023-2024 proxy season, 503 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 3,855 separate fund positions. On the most widely held item on that ballot — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — ALNYLAM PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALNYLAM PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALNYLAM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ALNYLAM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ALNYLAM PHARMACEUTICALS (ALNY) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alnylam-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.